A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (CEREN-2)

A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

EFC18419 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study with 3 treatment groups. The purpose of the study is to evaluate the efficacy, safety and tolerability of 2 dosing regimens of itepekimab compared to placebo as add-on therapy to intranasal corticosteroids (INCS) in male and female participants with chronic rhinosinusitis with nasal polyps (CRSwNP) aged 18 years of age and older.

Study details include:

• The study duration per participant (4-week screening, 52-week treatment, 20-week safety follow-up) will be up to 76 weeks. For participants transitioning to the LTS18420 study, the study duration will be 56 weeks.
• The treatment duration will be up to 52 weeks.
• The number of visits will be 9 site visits and 20 phone/home visits.

Study Overview

• Status: Active, not recruiting
• Conditions: Chronic Rhinosinusitis With Nasal Polyps
• Intervention / Treatment: Drug: Itepekimab (SAR440340); Drug: Placebo; Drug: Mometasone furoate nasal spray (MFNS)

• Study Type: Interventional
• Enrollment (Actual): 216
• Phase: Phase 3

Contacts and Locations

Study Locations

• Argentina
  • Buenos Aires, Argentina, 1414
    • Investigational Site Number : 0320001
  • Buenos Aires, Argentina, 1121
    • Investigational Site Number : 0320002
  • Corrientes, Argentina, 3400
    • Investigational Site Number : 0320004
  • Mendoza, Argentina, 5500
    • Investigational Site Number : 0320003
  • Tucumán Province
    • San Miguel de Tucumán, Tucumán Province, Argentina, 4000
      • Investigational Site Number : 0320005
• Australia
  • New South Wales
    • Bella Vista, New South Wales, Australia, 2153
      • Investigational Site Number : 0360003
  • Queensland
    • Brisbane, Queensland, Australia, 4029
      • Investigational Site Number : 0360002
  • Western Australia
    • Spearwood, Western Australia, Australia, 6163
      • Investigational Site Number : 0360001
• Belgium
  • Alken, Belgium, 3570
    • Investigational Site Number : 0560006
  • Ghent, Belgium, 9000
    • Investigational Site Number : 0560002
  • Leuven, Belgium, 3000
    • Investigational Site Number : 0560001
  • Namur
    • Gesves, Namur, Belgium, 5340
      • Investigational Site Number : 0560004
• Brazil
  • Paraná
    • Curitiba, Paraná, Brazil, 80810-100
      • Private Practice - Dr. Nelson Rosário- Site Number : 0760001
  • São Paulo
    • Marília, São Paulo, Brazil, 17504-072
      • Centro de Pesquisa Clínica de Marília - CPCLIM- Site Number : 0760002
    • Sorocaba, São Paulo, Brazil, 18040-425
      • Clinica de Alergia Martti Antila- Site Number : 0760003
    • São José do Rio Preto, São Paulo, Brazil, 15090-000
      • Fundação Faculdade Regional de Medicina de São José do Rio Preto- Site Number : 0760005
• Canada
  • British Columbia
    • Vancouver, British Columbia, Canada, V6A 2W1
      • Investigational Site Number : 1240017
  • Ontario
    • Burlington, Ontario, Canada, L7R 3P9
      • Investigational Site Number : 1240019
    • Cambridge, Ontario, Canada, N1R 8L4
      • Investigational Site Number : 1240015
    • Ottawa, Ontario, Canada, K1G 6C6
      • Investigational Site Number : 1240014
  • Quebec
    • Québec, Quebec, Canada, G1V 4W2
      • Investigational Site Number : 1240003
    • Québec, Quebec, Canada, G2J 0C4
      • Investigational Site Number : 1240012
• Chile
  • Biobio
    • Concepción, Biobio, Chile, 4070094
      • Investigational Site Number : 1520001
    • Talcahuano, Biobio, Chile, 2687000
      • Investigational Site Number : 1520004
  • Reg Metropolitana de Santiago
    • Santiago, Reg Metropolitana de Santiago, Chile, 7500505
      • Investigational Site Number : 1520003
  • Valparaiso
    • Quillota, Valparaiso, Chile, 2260877
      • Investigational Site Number : 1520002
• China
  • Baotou, China, 014040
    • Investigational Site Number : 1560020
  • Beijing, China, 100730
    • Investigational Site Number : 1560001
  • Chengdu, China, 610017
    • Investigational Site Number : 1560004
  • Chongqing, China, 400016
    • Investigational Site Number : 1560025
  • Hangzhou, China, 310003
    • Investigational Site Number : 1560019
  • Jinan, China, 250022
    • Investigational Site Number : 1560002
  • Jingzhou, China, 434020
    • Investigational Site Number : 1560012
  • Nanning, China, 530021
    • Investigational Site Number : 1560021
  • Shenyang, China, 110004
    • Investigational Site Number : 1560006
  • Suzhou, China, 215006
    • Investigational Site Number : 1560024
  • Taiyuan, China, 030001
    • Investigational Site Number : 1560017
  • Taiyuan, China, 030001
    • Investigational Site Number : 1560023
  • Wuhan, China, 430060
    • Investigational Site Number : 1560014
  • Yantai, China, 264001
    • Investigational Site Number : 1560003
  • Zibo, China, 255036
    • Investigational Site Number : 1560009
• Czechia
  • Hradec Králové, Czechia, 500 05
    • Investigational Site Number : 2030002
  • Pardubice, Czechia, 532 03
    • Investigational Site Number : 2030003
  • Pilsen, Czechia, 305 99
    • Investigational Site Number : 2030005
  • Prague, Czechia, 100 34
    • Investigational Site Number : 2030004
  • Prague, Czechia, 150 06
    • Investigational Site Number : 2030001
• Denmark
  • Aarhus, Denmark, 8200
    • Investigational Site Number : 2080001
  • Copenhagen, Denmark, 2100
    • Investigational Site Number : 2080004
  • Køge, Denmark, 4600
    • Investigational Site Number : 2080002
• France
  • Bordeaux, France, 33076
    • Investigational Site Number : 2500011
  • Marseille, France, 13005
    • Investigational Site Number : 2500004
  • Nantes, France, 44093
    • Investigational Site Number : 2500001
  • Poitiers, France, 86021
    • Investigational Site Number : 2500010
  • Pontoise, France, 95300
    • Investigational Site Number : 2500014
  • Toulouse, France, 31059
    • Investigational Site Number : 2500007
• Germany
  • Dresden, Germany, 01307
    • Investigational Site Number : 2760001
  • Dresden, Germany, 01139
    • Investigational Site Number : 2760006
  • Hamburg, Germany, 20246
    • Investigational Site Number : 2760005
  • Leipzig, Germany, 04103
    • Investigational Site Number : 2760002
  • Mainz, Germany, 55131
    • Investigational Site Number : 2760007
  • Villingen-Schwenningen, Germany, 78052
    • Investigational Site Number : 2760008
• Hungary
  • Budapest, Hungary, 1026
    • Investigational Site Number : 3480005
  • Szeged, Hungary, 6720
    • Investigational Site Number : 3480001
• Israel
  • Haifa, Israel, 3104802
    • Investigational Site Number : 3760003
  • Jerusalem, Israel, 9112001
    • Investigational Site Number : 3760004
  • Nahariya, Israel, 2210001
    • Investigational Site Number : 3760001
  • Rehovot, Israel, 7610001
    • Investigational Site Number : 3760002
• Italy
  • Catania, Italy, 95123
    • Investigational Site Number : 3800003
  • Milano
    • Milan, Milano, Italy, 20132
      • Investigational Site Number : 3800001
  • Napoli
    • Naples, Napoli, Italy, 80131
      • Investigational Site Number : 3800005
• Japan
  • Toyama, Japan, 939-2716
    • Investigational Site Number : 2500005
• Mexico
  • Chihuahua City, Mexico, 31217
    • Investigational Site Number : 4840007
  • Veracruz, Mexico, 91900
    • Investigational Site Number : 4840002
  • Jalisco
    • Guadalajara, Jalisco, Mexico, 44100
      • Investigational Site Number : 4840001
  • Nuevo León
    • Monterrey, Nuevo León, Mexico, 64718
      • Investigational Site Number : 4840008
• Netherlands
  • Amsterdam, Netherlands, 1081 HV
    • Investigational Site Number : 5280002
  • Utrecht, Netherlands, 3584 CX
    • Investigational Site Number : 5280001
• Poland
  • Greater Poland Voivodeship
    • Poznan, Greater Poland Voivodeship, Poland, 60-693
      • Investigational Site Number : 6160004
  • Lower Silesian Voivodeship
    • Wroclaw, Lower Silesian Voivodeship, Poland, 50-750
      • Investigational Site Number : 6160005
  • Lódzkie
    • Lodz, Lódzkie, Poland, 90-302
      • Investigational Site Number : 6160002
  • Silesian Voivodeship
    • Bielsko-Biala, Silesian Voivodeship, Poland, 43-300
      • Investigational Site Number : 6160001
• Romania
  • Brasov, Romania, 500283
    • Investigational Site Number : 6420002
  • Brasov, Romania, 500091
    • Investigational Site Number : 6420003
  • Bucharest, Romania, 022328
    • Investigational Site Number : 6420001
• Spain
  • Madrid, Spain, 28034
    • Investigational Site Number : 7240010
  • Madrid, Spain, 28040
    • Investigational Site Number : 7240012
  • Barcelona [Barcelona]
    • Barcelona, Barcelona [Barcelona], Spain, 08003
      • Investigational Site Number : 7240006
  • Cantabria
    • Santander, Cantabria, Spain, 39008
      • Investigational Site Number : 7240002
  • Catalunya [Cataluña]
    • L'Hospitalet de Llobregat, Catalunya [Cataluña], Spain, 08907
      • Investigational Site Number : 7240004
  • Navarre
    • Pamplona, Navarre, Spain, 31008
      • Investigational Site Number : 7240008
• Turkey (Türkiye)
  • Ankara, Turkey (Türkiye), 06230
    • Investigational Site Number : 7920003
  • Bursa, Turkey (Türkiye), 16059
    • Investigational Site Number : 7920001
  • Istanbul, Turkey (Türkiye), 34360
    • Investigational Site Number : 7920002
• United Kingdom
  • Lancashire
    • Wigan, Lancashire, United Kingdom, Wn6 9ep
      • Investigational Site Number : 8260002
  • London, City of
    • London, London, City of, United Kingdom, W2 1NY
      • Investigational Site Number : 8260001
  • Somerset
    • Taunton, Somerset, United Kingdom, TA1 5DA
      • Investigational Site Number : 8260003
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35244
      • Excel ENT of Alabama- Site Number : 8400052
  • California
    • La Mesa, California, United States, 91942
      • Velocity Clinical Research - San Diego- Site Number : 8400041
    • Los Angeles, California, United States, 90048
      • Cedars-Sinai Medical Center- Site Number : 8400030
    • Napa, California, United States, 94558
      • One Of A Kind Clinical Research Center- Site Number : 8400034
  • Florida
    • Jacksonville, Florida, United States, 32209
      • University of Florida - Jacksonville- Site Number : 8400053
    • New Port Richey, Florida, United States, 34653
      • Advanced Research Institute - New Port Richey- Site Number : 8400014
  • Illinois
    • Chicago, Illinois, United States, 60607
      • University of Illinois at Chicago- Site Number : 8400003
  • Kentucky
    • Louisville, Kentucky, United States, 40220
      • Advanced ENT & Allergy - Louisville- Site Number : 8400007
  • Louisiana
    • Lafayette, Louisiana, United States, 70508
      • Velocity Clinical Research - Lafayette- Site Number : 8400026
  • Maryland
    • Baltimore, Maryland, United States, 21287
      • Johns Hopkins Hospital- Site Number : 8400017
  • Ohio
    • Cincinnati, Ohio, United States, 45219
      • University of Cincinnati Medical Center- Site Number : 8400022
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73120
      • Allergy, Asthma and Clinical Research- Site Number : 8400002
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19107
      • Thomas Jefferson University Hospital- Site Number : 8400044
  • South Carolina
    • Greer, South Carolina, United States, 29650
      • Spartanburg-Greer ENT & Allergy- Site Number : 8400039
  • Texas
    • Fort Worth, Texas, United States, 76104
      • Ear and Sinus Institute- Site Number : 8400048

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Participants must be 18 years of age or older.
• Participants with a history of chronic rhinosinusitis with nasal polyps (CRSwNP) for at least 1 year prior to screening

• Participants must have at least one of the following features:

  • Prior sinonasal surgery for nasal polyps (NP).
  • Worsening symptoms of chronic rhinosinusitis (CRS) requiring treatment with systemic corticosteroid(s) (SCS) within the prior 1 year before screening (Visit 1).
• An endoscopic bilateral Nasal Polyp Score (NPS) of at least 5 out of maximum score of 8 (with a minimum score of 2 in each nasal cavity) at screening and randomization.

• Ongoing symptoms (for at least 12 weeks before Visit 1) of:

  • Nasal congestion/blockade/obstruction with moderate or severe (symptom severity score 2 or 3) at Visit 1 and a weekly average severity of greater than 1 in the week before randomization (Visit 2), AND
  • At least one of the following two symptoms: loss of smell or rhinorrhea (anterior/posterior).

• A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:

  • Is not a women of childbearing potential (WOCBP), OR
  • Is a WOCBP and agrees to use a contraceptive method that is highly effective, with a failure rate of <1% during the study (at a minimum until 20 weeks after the last dose of study intervention).

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

• Participants with a history of clinically significant renal, hepatic, metabolic, neurologic, hematologic, ophthalmologic, respiratory (excluding those with asthma and aspirin-exacerbated respiratory disease (AERD) which may be included in the study), gastrointestinal, cardiovascular, cerebrovascular, or other significant medical illness or disorder, which, in the judgment of the Investigator, could interfere with the study or require treatment that might interfere with the study.
• Participants who are currently smoking tobacco and/or vaping, or participants in whom smoking/vaping cessation has occurred <6 months prior to Screening (Visit 1). Nicotine replacement therapy and/or noninhaled tobacco product use are not considered current smoking of tobacco.
• Participants meet any contraindications for mometasone furoate nasal spray (MFNS) such as hypersensitivity to MFNS or any of its components; or participants with uncontrolled opportunistic infections.
• Participants with a history of a severe systemic hypersensitivity reaction to a mAb.
• Participants with conditions/concomitant diseases making them non-evaluable at Visit 1 or for the primary efficacy endpoint.
• Participants with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc).
• Participants with severe uncontrolled asthma with history of 2 and/or more exacerbations, requiring SCS or 1 hospitalization requiring SCS in the past year.
• History of concomitant lung disease (other than asthma, eg, COPD, interstitial lung disease) which in the opinion of the Investigator could interfere with performance and interpretation of spirometry.
• Participants treated with intranasal corticosteroid(s) (INCS) (MFNS is permitted), intranasal emitting devices/stents, nasal spray using exhalation delivery system such as XhanceTM during the screening period. In Japan and China INCS other than MFNS are permitted.
• Participants who have undergone any sinus intranasal surgery (including polypectomy) within 6 months before Visit 1.
• Participants who received SCS 1 month prior to Screening (Visit 1) or during the screening period (between Visit 1 and Visit 2).
• Known allergy to itepekimab or its excipients, or any drug or other allergy that, in the opinion of the Investigator, contraindicates participation in this study.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Itepekimab high dose; Subcutaneous (SC) administration of Itepekimab high dose for 52 weeks	Drug: Itepekimab (SAR440340); Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous; Other Names: REGN3500; Drug: Mometasone furoate nasal spray (MFNS); Pharmaceutical form: Solution for administration via spray pump. Route of administration: Intranasal spray
Experimental: Itepekimab low dose; SC administration of Itepekimab low dose for 52 weeks	Drug: Itepekimab (SAR440340); Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous; Other Names: REGN3500; Drug: Placebo; Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous; Drug: Mometasone furoate nasal spray (MFNS); Pharmaceutical form: Solution for administration via spray pump. Route of administration: Intranasal spray
Placebo Comparator: Placebo; SC administration of matching placebo for 52 weeks	Drug: Placebo; Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous; Drug: Mometasone furoate nasal spray (MFNS); Pharmaceutical form: Solution for administration via spray pump. Route of administration: Intranasal spray

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in the endoscopic NPS	The Nasal Polyp Score (NPS) is the sum of the right and left nostril scores, as evaluated by means of nasal endoscopy. Nasal polyp is graded based on polyp size from 0 to 4 with higher scores indicating larger polyps. The sum of right and left nostril scores ranges from 0 (no polyps) to 8 (large polyps).	Baseline to Week 24
Change from baseline in the NCS	The Nasal Congestion Score (NCS) is scored using a 0-3 categorical scale where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms. Outcome value is defined as the preceding 28-day average of morning scores recorded in eDiary.	Baseline to Week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in endoscopic NPS	The NPS is the sum of the right and left nostril scores, as evaluated by means of nasal endoscopy. Nasal polyp is graded based on polyp size from 0 to 4 with higher scores indicating larger polyps. The sum of right and left nostril scores ranges from 0 (no polyps) to 8 (large polyps).	Baseline to Week 52
Change from baseline in NCS	The NCS is scored using a 0-3 categorical scale where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms. Outcome value is defined as the preceding 28-day average of morning scores recorded in eDiary.	Baseline to Week 52
Change from baseline in opacification of sinuses assessed by Computed Tomography (CT) scan using the LMK score	The Lund-Mackay (LMK) system is based on localization with points given for degree of opacification: 0 = normal, 1 = partial opacification, 2 = total opacification. These points are then applied to the maxillary, anterior ethmoid, posterior ethmoid, sphenoid, frontal sinus on each side. The osteomeatal complex is graded as 0 = not occluded, or 2 = occluded, deriving a maximum score of 12 per side. The total score is the sum of scores from each side and ranges from 0 (normal) to 24 (total opacification).	Baseline to Week 24
Change from baseline in the TSS (nasal congestion/obstruction, anterior/posterior rhinorrhea, and loss of sense of smell)	The CRSwNP Total Symptom Score (TSS) is a composite score derived from nasal congestion (NC)/obstruction, anterior/posterior rhinorrhea, and loss of smell. The total score ranges from 0 to 9 with higher scores on TSS indicating greater overall symptom severity.	Baseline to Weeks 24 and 52
Change from baseline in loss of smell severity score using the daily CRSwNP sinonasal symptom eDiary, and UPSIT score	The CRSwNP sinonasal symptom diary is designed to assess the severity of chronic rhinosinusitis (CRS) sinonasal symptoms on daily basis. These symptoms include NC/obstruction, anterior rhinorrhea and posterior rhinorrhea, facial pain/pressure, loss of smell, and headache. Each of the individual items of the diary are scored from 0 ("No symptoms") to 3 ("Severe symptoms - symptoms that are hard to tolerate, cause interference with activities or daily living"). Higher scores on the items of the individual symptoms denote greater symptom severity. The University of Pennsylvania Smell Identification Test (UPSIT) test is a rapid and easy-to-administer method to quantitatively assess human olfactory function. The total score ranges from 0 (anosmia) to 40 (normosmia).	Baseline to Weeks 24 and 52
Change from baseline in SNOT-22 total score	The Sino-Nasal Outcome Test-22-Items (SNOT-22) is a patient-reported outcome questionnaire designed to assess the impact of CRS on patient's Health-Related Quality of Life (HRQoL). It has 22 items covering five domains: Nasal, Ear/Facial, Sleep, Function, and Emotion. A global score ranging from 0 to 110 with higher score indicating greater rhinosinusitis related health burden.	Baseline to Weeks 24 and 52
Change from baseline in PROMIS SD-SF-8b scores	The Patient Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance - Short Form 8b (SD-SF-8b) is a generic 8-item sleep disturbance assessment that evaluates difficulties with falling asleep, staying asleep, and getting enough sleep; and perceptions on the quality and satisfaction of sleep. Scores are calculated with a conversion of the raw score (score range 8 to 40) into a standardized T-score with the mean of the 50 and SD of 10, where higher scores indicate more disturbed sleep.	Baseline to Weeks 24 and 52
Proportion of participants with CRSwNP requiring systemic corticosteroid(s) (SCS) or surgery for CRS		Baseline up to Week 52
Annualized rate of SCS course or surgery for CRS		Baseline up to Week 52
Time to first either SCS or surgery for CRS		Baseline through Week 52
Change from baseline in pre-BD FEV1 (in mL) in participants with co-morbid asthma	Pre-BD FEV1: pre-bronchodilator forced expiratory volume in 1 second	Baseline to Weeks 24 and 52
Change from baseline in ACQ-5 score in participants with co-morbid asthma	The Asthma Control Questionnaire (ACQ) is a questionnaire that measures the adequacy of asthma control and any changes in asthma control that may occur spontaneously or as a result of treatment. The ACQ-5 has 5 questions on the asthma symptoms. The global score is the mean of the item responses and ranges from 0 and 6 with higher score indicating lower asthma control.	Baseline to Weeks 24 and 52
Change from the baseline in NPS and NCS in the subgroup of patients with aspirin-exacerbated respiratory disease (AERD)		Baseline to Weeks 24 and 52
Proportion of participants with AERD requiring SCS or surgery for CRS		Baseline up to Week 52
Annualized rate of SCS course or surgery for CRS in participants with AERD		Baseline up to Week 52
Time to first either SCS or surgery for CRS in participants with AERD		Baseline through Week 52
Change from baseline in pre-BD FEV1 (in ml) in participants with AERD	Pre-BD FEV1: pre-bronchodilator forced expiratory volume in 1 second	Baseline to Weeks 24 and 52
Proportion of NPS responders (defined as participants with improvement by at least 1 point in NPS)		Weeks 24 and 52
Proportion of NPS responders (defined as participants with improvement by at least 2 points in NPS)		Weeks 24 and 52
Incidence of treatment-emergent adverse Events (TEAEs), treatment-emergent serious adverse events (TESAEs), treatment-emergent adverse events of special interest (TEAESIs) and TEAEs leading to treatment discontinuation		Baseline to End of Study (EOS) (Week 72)
Itepekimab concentration in serum		Baseline to EOS (Week 72)
Incidence of treatment-emergent anti-itepekimab antibody (ADA) responses		Baseline to EOS (Week 72)

Collaborators and Investigators

• Sponsor: Sanofi
• Collaborators: Regeneron Pharmaceuticals
• Investigators: Study Director: Clinical Sciences & Operations, Sanofi

Publications and helpful links

Helpful Links

• EFC18419 Plain Language Results Summary

Study record dates

Study Major Dates

• Study Start (Actual): February 6, 2025
• Primary Completion (Estimated): November 6, 2026
• Study Completion (Estimated): October 11, 2027

Study Registration Dates

• First Submitted: February 14, 2025
• First Submitted That Met QC Criteria: February 14, 2025
• First Posted (Actual): February 19, 2025

Study Record Updates

• Last Update Posted (Actual): June 2, 2026
• Last Update Submitted That Met QC Criteria: June 1, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathological Conditions, Anatomical; Respiratory Tract Infections; Infections; Respiratory Tract Diseases; Nose Diseases; Otorhinolaryngologic Diseases; Rhinitis; Paranasal Sinus Diseases; Rhinosinusitis; Polyps; Nasal Polyps; Sinusitis; Anti-Inflammatory Agents; Dermatologic Agents; Anti-Allergic Agents; itepekimab
• Other Study ID Numbers: EFC18419; 2024-516815-26 (Registry Identifier: CTIS); U1111-1306-6544 (Registry Identifier: ICTRP)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No